(Medicana Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Bursa, Türkiye)
(Uludağ Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa, Türkiye)
Hikmet ÖZTOP
(Uludağ Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa, Türkiye)
(Uludağ Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Bursa, Türkiye)
Özen Öz GÜL
(Uludağ Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Bursa, Türkiye)
(Uludağ Üniversitesi, Tıp Fakültesi, Biyoistatistik Anabilim Dalı, Bursa, Türkiye)
(Uludağ Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Bursa, Türkiye)
(Uludağ Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Bursa, Türkiye)
Yıl: 2020Cilt: 24Sayı: 4ISSN: 1301-2193 / 1308-9846Sayfa Aralığı: 253 - 260İngilizce

25 0
Demographic and Clinical Features of Medullary Thyroid Carcinoma
Objective: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor affecting the parafollicular C cells of the thyroid gland. This study aimedto analyze demographic and clinical factors that might affect the prognosis of MTC andevaluate the long-term outcomes of surgery in MTC patients at a single center. Material and Methods: A total of 36 patients with a confirmed MTC diagnosis based on histopathological examination and underwent surgeryduring 2000–2015 were examined. Archived files of these patients were reviewed, and data on clinical, biochemical, and radiological test results were assessed. Factors affecting disease-free survival were also evaluated. Results: Theduration of the follow-up of the patients was 80.3±76.1 months. MEN2A was detected in three patients (8.3%). Twelve patients (33.3%) had metastasis at the time of diagnosis. During the follow-up period, local recurrence was observed in 13 (36.1%) patients. Nine patients (25%) presented metastasis at follow-up. The mean disease-free survival was high in sporadic MTC compared to hereditary MTC. Conclusion: The study observed asignificant contribution tothe hereditary nature of the disease on prognosis. However,other prognostic factors such as gender, nodule characteristics, recurrence and metastasis, and treatment modalities did differsignificant. Patients with MTC should be evaluated to know if the disease is sporadic or hereditary. The small sample size in this study restricts the power of statistical analysis;therefore, further prospective studies are necessary to reveal the other contributory prognostic factors in MTC.
DergiAraştırma MakalesiErişime Açık
  • 1. Geller G, Laskin J, Cheung WY, Ho C. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res. 2017;10:6. [Crossref] [PubMed] [PMC]
  • 2. Calvo J, Torrealba G, Sáenz A, Santamaría C, Morera E, Alvarado S, Roa Y, González M. Genetic and clinical features of medullary thyroid carcinoma: the experience of a single center in Costa Rica. J Cancer Epidemiol. 2016;2016:9637173. [Crossref] [PubMed] [PMC]
  • 3. Maciel LMZ, Magalhães PKR. Medullary thyroid carcinoma - adverse events during systemic treatment: risk-benefit ratio. Arch Endocrinol Metab. 2017;61:398-402. [Crossref] [PubMed]
  • 4. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567-610. [Crossref] [PubMed] [PMC]
  • 5. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33:493-497. [Crossref] [PubMed]
  • 6. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034. [Crossref] [PubMed]
  • 7. Lee CR, Lee S, Son H, Ban E, Kang SW, Lee J, Jeong JJ, Nam KH, Chung WY, Park CS. Medullary thyroid carcinoma: a 30-year experience at one institution in Korea. Ann Surg Treat Res. 2016;91:278-287. [Crossref] [PubMed] [PMC]
  • 8. Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Res. 2017;6:2184. [Crossref] [PubMed] [PMC]
  • 9. Kim BH, Kim IJ. Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2016;31:392-399. [Crossref] [PubMed] [PMC]
  • 10.Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997;103:60-69. [Crossref] [PubMed]
  • 11.Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655- 2663. [Crossref] [PubMed]
  • 12.Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537-1542. [Crossref] [PubMed] [PMC]
  • 13.Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998;48:265-223. [Crossref] [PubMed]
  • 14.Raue F, Frank-Raue K. Long-term follow-up in medullary thyroid carcinoma. Recent Results Cancer Res. 2015;204:207-225. [Crossref] [PubMed]
  • 15.Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305-310. [Crossref] [PubMed]
  • 16.Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol. 2010;102:175- 178. [Crossref] [PubMed] [PMC]
  • 17.Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-141. [Crossref] [PubMed] [PMC]
  • 18.Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322:2-7. [Crossref] [PubMed]
  • 19.Raue F, Bruckner T, Frank-Raue K. Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center. J Clin Endocrinol Metab. 2019;104:4264- 4272. [Crossref] [PubMed]
  • 20.Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. J Clin Endocrinol Metab. 2017;102:2807-2813. [Crossref] [PubMed] [PMC]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.